Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
61 participants
INTERVENTIONAL
2016-05-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RT group
combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
DP-R213
Investigational product is prescribed to all of randomized subjects
Raloxifene
Investigational product is prescribed to all of randomized subjects
Cholecaliferol
Investigational product is prescribed to all of randomized subjects
TR group
combination dose of Raloxifene and Cholecaliferol and DP-R213 in order
DP-R213
Investigational product is prescribed to all of randomized subjects
Raloxifene
Investigational product is prescribed to all of randomized subjects
Cholecaliferol
Investigational product is prescribed to all of randomized subjects
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DP-R213
Investigational product is prescribed to all of randomized subjects
Raloxifene
Investigational product is prescribed to all of randomized subjects
Cholecaliferol
Investigational product is prescribed to all of randomized subjects
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed the informed consent form prior to the study participation
Exclusion Criteria
* Previously donate whole blood within 2 months or component blood within 1 month
* Clinically significant allergic disease
* Taken IP in other trial within 3 months
* An impossible one who participates in clinical trial by investigator's decision including laboratory test result
19 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alvogen Korea
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DP-CTR213-I-01
Identifier Type: -
Identifier Source: org_study_id